👋 Hey, let’s get into it. Revolution Medicines is starting to get the kind of hype normally reserved for companies with stadium naming rights and armies of bankers pitching acquisition decks.

A month after posting pancreatic cancer data that doubled survival in heavily pretreated patients, analysts at Truist are already calling the company “the next oncology titan.” That’s a pretty loaded label in an industry where most “future giants” get acquired before they ever have the chance to become one. Once Wall Street starts throwing around words like “dynasty,” someone usually shows up with a checkbook.

In fact, Merck reportedly already did. The pharma giant was said to be in talks to buy Revolution earlier this year for somewhere between $28 billion and $32 billion before negotiations fell apart over price. Apparently Revolution looked at a number bigger than the GDP of some countries and said, “you’re gonna have to do better than that.”

💰 Regeneron Bets $2.3B on “Undruggable” Targets
Regeneron is paying $125 million upfront plus equity to partner with Parabilis Medicines on a new class of antibody-Helicon conjugates, or AHCs, designed to attack intracellular proteins traditional drugs struggle to reach. The platform uses stabilized peptides called Helicons that can bind to flat protein surfaces typically considered “undruggable.” Regeneron plans to explore both standalone Helicon therapies and antibody-linked versions that function similarly to ADCs. The deal spans five initial targets and could ultimately reach $2.2 billion in milestones.

🩸 AstraZeneca’s $1.3B Hypertension Bet Just Paid Off
AstraZeneca officially turned its 2023 acquisition of CinCor Pharma into an FDA approval after Baxfendy became the first aldosterone synthase inhibitor cleared for uncontrolled hypertension in the U.S. The drug works by blocking aldosterone production, giving AZ a novel mechanism in one of medicine’s largest cardiovascular markets. The approval was backed by late-stage data showing statistically significant blood pressure reductions in patients already taking multiple therapies. AstraZeneca believes the drug could eventually surpass $5 billion in peak annual sales.

🚪 FDA Leadership Chaos Keeps Escalating
Just days after FDA chief Marty Makary “resigned,” CDER chief Dr. Tracy Beth Høeg has exited the agency following a mere five months in the role. Her departure adds to an already chaotic stretch defined by missed deadlines, staff departures, and mounting industry frustration over regulatory unpredictability. Høeg had drawn controversy for publicly revisiting safety concerns around products the FDA had already approved, including RSV therapies for infants. Meanwhile, more than 100 biotech and pharma leaders are now publicly urging longtime oncology regulator Richard Pazdur to return as FDA commissioner. The industry is basically asking for the regulatory version of a veteran emergency quarterback. It’s unclear if he even wants the gig.

✅ Enhertu Nabs Dual Approval in Breast Cancer
Daiichi Sankyo and AstraZeneca secured dual FDA approvals expanding Enhertu into both neoadjuvant and adjuvant HER2-positive early breast cancer treatment.

😕 Regeneron’s Melanoma Bet Falls Short
Regeneron’s phase 3 melanoma trial for fianlimab missed its primary endpoint after failing to outperform Merck’s blockbuster PD-1 therapy Keytruda.

🏭 Bristol Myers Eyes $1B Texas Expansion
Bristol Myers Squibb is considering a $1 billion Houston manufacturing plant that could employ nearly 500 workers and expand over time.

🙃 REGENXBIO Lands Duchenne Win…Sort Of
REGENXBIO hit the primary endpoint in Duchenne muscular dystrophy, though serious adverse events sent shares tumbling 37% after the mixed update.

✅ Roche Turns ctDNA Into Another Approval
Roche secured a new bladder cancer approval for Tecentriq using Natera’s Signatera test to guide treatment through circulating tumor DNA detection.

🤺 BeOne Enters the BCL-2 Fight
BeOne’s Beqalzi became the first FDA-approved BCL-2 inhibitor specifically cleared for mantle cell lymphoma after prior BTK inhibitor treatment.

🧠 Eisai Nears Blockbuster Status for Alzheimer’s Drug
Eisai now expects nearly $905 million in annual Leqembi sales as the Alzheimer’s drug slowly inches toward blockbuster territory.

🏆 AstraZeneca Keeps Winning in Bladder Cancer
AstraZeneca reported another positive phase 3 bladder cancer readout for Imfinzi, adding more pressure on Merck’s Keytruda dominance.

Pharma companies hoping to dodge Trump’s proposed 100% drug tariffs just learned the catch: the federal government wants receipts. Lots of them.

The Department of Commerce released details explaining how companies can qualify for reduced tariff rates on patented pharmaceuticals and ingredients. The basic deal is simple. Promise to move manufacturing into the United States, and the government may lower your tariff burden from 100% to 20%. But the application process reads less like paperwork and more like an IRS audit mixed with a supply-chain confession booth.

Drugmakers now have to disclose manufacturing locations, contract manufacturing partners, API sourcing, projected U.S. production levels, planned investments through 2029, and detailed onshoring timelines. Companies must also submit audited progress reports every six months. And if regulators believe a company exaggerated or misled the government about its plans? The full tariff rate can reportedly snap back into place retroactively.

The timing is brutal. Applications are due June 12, while the tariffs themselves begin rolling out later this year. That means companies are scrambling to map supply chains that have spent decades optimizing for cost efficiency, not geopolitical survival. Consulting firms are already telling clients to rapidly assemble manufacturing data across their entire portfolios.

The bigger story here is that pharmaceutical manufacturing has become national security policy. For years, companies treated global supply chains as purely financial decisions. Now they’re becoming political liabilities. Pharma executives are discovering that in 2026, “Where is this drug made?” matters almost as much as “Does this drug work?”

That’s how many deaths in Japan have reportedly been linked to serious liver dysfunction in patients treated with Amgen’s rare disease drug Tavneos. Partner company Kissei Pharmaceutical has now asked doctors to stop prescribing the drug to new patients while ongoing cases are reviewed.

Here’s what biotech Redditors are talking about:

😬 Is U.S. Biotech Slowly Outsourcing Innovation?
A Reddit debate this week explored a “doomsday” scenario where China increasingly dominates early biotech innovation while the U.S. becomes mostly a manufacturing and commercialization engine. Some commenters argued the cost advantages are becoming impossible to ignore, with one person claiming China can hire four PhD scientists for the price of one in a major U.S. biotech hub. Others pushed back hard, saying FDA standards, clinical trial quality, and global trust still heavily favor U.S.-led development. The anxiety underneath the discussion felt very real, though.

💼 Biotech’s Job Market Doom Spiral
Another Reddit thread turned into a therapy session about biotech hiring anxiety. Some users argued the r/biotech subreddit overrepresents unemployed scientists and spreads constant pessimism, while others said the fear is justified because even employed workers worry they could spend a year unemployed if layoffs hit. One commenter with a PhD said they had only received one interview after applying for jobs over two years. The vibe was less “temporary downturn” and more “everyone’s quietly stress-refreshing LinkedIn.”

🦠 Ebola Is Suddenly Back in the Headlines
More than 300 suspected Ebola cases and 88 suspected deaths have now been reported across central Africa as global concern rapidly escalates.

😬 Sun Pharma Recalls Cancer Drug Over Glass Particles
Sun Pharma pulled a batch of chemotherapy drug vials from the U.S. market after discovering glass particles inside some products.

💉 Botox May Finally Have a Serious Rival
Ipsen shared phase 2 data suggesting its long-acting anti-wrinkle injectable could outperform traditional Botox-style neurotoxins on durability.

⚖️ SCOTUS Preserves Telehealth Abortion Access
The Supreme Court temporarily blocked a lower court ruling that would have restricted telehealth prescribing and mail distribution of mifepristone.

🧪 Create Medicines Wants CAR-T Without the Extraction Process
Create Medicines just raised $122 million to push its in vivo CAR-T platform deeper into autoimmune disease and oncology. Instead of removing and engineering immune cells outside the body, the company uses mRNA-LNP technology designed to program T cells directly inside patients. The startup was originally launched as Myeloid Therapeutics by Siddhartha Mukherjee and Ronald Vale before rebranding in 2023. In vivo CAR-T has quickly become one of biotech’s hottest arms races, and investors clearly do not want to miss the next wave.

🌡️ May 19, 1743 — Celsius Finally Started Making Sense
On this day in 1743, French physicist Jean-Pierre Christin introduced the centigrade temperature scale using what now feels like the extremely obvious setup: water freezes at 0 and boils at 100. Revolutionary stuff. Before that, the Celsius system bizarrely ran backward, with boiling at 0 and freezing at 100. Nearly 300 years later, most of the world adopted the cleaner version… while the United States looked at water freezing at 32 and boiling at 212 and said, “Yeah, let’s keep that one.”

Last week everyone was panic-googling hantavirus. This week it’s Ebola. Can’t wait to see what next week brings. Smallpox? Bubonic plague? A surprise comeback tour from polio? At least public health leadership is looking super stable right now. 🙃

That’s all for today. See you Thursday for the next issue. 👋

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead